DGAP-News According to the preliminary IFRS financial statements for the 2020 financial year, HAEMATO AG increased its revenue by 20.5 % to EUR 238.3 million and increased EBITDA by 74.8 % to EUR 3.3 million
DGAP-News: HAEMATO AG / Key word(s): Preliminary Results
Corporate News of HAEMATO AG:
According to the preliminary IFRS financial statements for the 2020 financial year, HAEMATO AG increased its revenue by 20.5 % to EUR 238.3 million and increased EBITDA by 74.8 % to EUR 3.3 million.
In the 2020 financial year, HAEMATO AG, Schoenefeld (ISIN: DE000289VV1), achieved IFRS consolidated revenues of EUR 238.3 million (previous year: EUR 197.8 million), a result from ordinary activities (EBITDA) of EUR 3.3 million (previous year: EUR 1.9 million), an operating result (EBIT) of EUR 1.6 million (previous year: EUR -19 thousand) and net income after special effects related to the reporting date of EUR -4.8 million (previous year: EUR -1.2 million). The gross margin increased from 6.87% (previous year) to 7.42% in 2020.
The special effects of EUR -5.4 million (previous year: EUR -0.7 million) included in the net profit for the year relate to a non-cash, reporting-date-related valuation of financial assets (company participations) at fair value (stock market prices) as of 31 December 2020. The company assumes that there is considerable catch-up potential in this respect in the coming years.
The operating cash flow improved significantly in the past financial year due to optimised working capital management and amounted to EUR 14.7 million (previous year: EUR -2.8 million). Net cash flow increased from EUR -3.4 million (previous year) to EUR 9.3 million in 2020.
The equity ratio increased from 56.2% (previous year) to 74.2%. Liabilities decreased by 22.7 % to EUR 43.6 million (previous year: EUR 56.3 million). Liabilities to banks fell in 2020 by EUR 7.1 million (corresponds to 28.1%) from EUR 25.2 million to EUR 18.1 million as of the balance sheet date 31 December 2020.
As one of the leading suppliers of special pharmaceuticals, the HAEMATO Group benefits from competition in the primary health care market. The specialisation in drugs for the treatment of chronic diseases and for individual therapies leads us to expect a positive development in the future due to the demographic development. We expect the positive sales development of the past financial year to continue in the 2021 financial year and anticipate sales growth to EUR 260 to 290 million and an improvement in EBIT in the current financial year to EUR 7 to 9 million. The expected significant increase in EBIT in 2021 is the result of implementing the new strategy of focusing on high-margin business areas.